IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis (NASDAQ: IMCC) signed a non-binding letter of intent dated March 17, 2026 to acquire 51% of Blackaxe Technologies, a Polish defense-tech firm focused on satellite intelligence, AI imagery analytics and counter-UAS/cyber interception solutions.
The proposed deal would diversify IMC beyond medical cannabis into defense and homeland security; completion is subject to due diligence, definitive agreements and regulatory approvals, and may not occur.
IM Cannabis (Nasdaq: IMCC) raised US$2,171,660.40 via two arm's‑length note financings announced Jan 26, 2026.
The First Note (issued Jan 7, 2026) has principal US$1,538,749 after a 10% issuance discount, 8% interest (rises to 14% on default), 18‑month maturity with lender extension option, conversion at the lower of US$1.47 or 90% of 20‑day low VWAP (floor US$0.29), and 228,150 five‑year warrants at C$3.45. The Second Note (issued Jan 20, 2026) has principal US$632,911.50 after 10% discount, identical interest and maturity terms, conversion at the lower of US$1.38 or 90% of 20‑day low VWAP (floor US$0.275), and 93,671 five‑year warrants at C$3.45.
Approximately US$500,000 of proceeds were used to repay existing creditors; the company agreed to file an F-3 registration within 30 trading days. All securities are subject to a four‑month and one‑day hold.
IM Cannabis (Nasdaq: IMCC) announced the appointment of Alon Dayan to its board of directors effective December 31, 2025. The company operates in Israel and Germany and named Dayan for his executive experience in homeland security technology and systems integration.
Dayan is CEO of KeepZone AI since 2025 and founder/CEO of L1-Systems since 2014, where he led projects in homeland security, intelligence systems and telecommunications across Latin America, Eastern Europe, and Western Europe. His prior roles include CEO of Virtual Crypto Technologies and business development at Elbit Systems. He holds a B.A. in Electrical and Electronic Engineering from Ariel University.
IM Cannabis (Nasdaq: IMCC) announced on Dec 30, 2025 that it is evaluating strategic options to enter the U.S. cannabis market after President Trump's Dec 18, 2025 executive order directing rescheduling of marijuana toward Schedule III. The company engaged SSC Advisors to provide financial advisory services to support potential U.S. market entry, identify partners or acquirors, and manage transaction processes related to its German and Israeli operations. IM Cannabis said it will continue monitoring federal rescheduling developments as it assesses possible divestitures and U.S. expansion opportunities.
IM Cannabis (Nasdaq: IMCC) appointed Asi Levi, CPA as Chief Financial Officer effective December 12, 2025, replacing Uri Birenberg.
Mr. Levi has over 15 years of finance experience, including prior CFO roles at Water Ways Technologies and DekelOil CI and controller roles at SciSparc and A2Z Cust2Mate. The company said he oversaw fundraising, financial planning, budgeting and cash flow management under IFRS and other standards. The company thanked Mr. Birenberg for his service and wished him success in future endeavors.
IM Cannabis (NASDAQ: IMCC) reported Q3 2025 results for the quarter and nine months ended September 30, 2025, with amounts in Canadian dollars.
Key Q3 2025 figures: Revenue $13.9M (flat vs. Q3 2024), Gross profit $2.7M (down 13%), Gross margin 20% (from 23%), One-time goodwill and intangible impairment $3.1M, Operating expenses $6.9M (up 68%), and Net loss $3.9M. Non-IFRS Adjusted EBITDA loss was $0.6M. Cash and restricted cash totaled $2.3M as of September 30, 2025. Total assets rose to $44.3M and total liabilities to $40.0M. The company included a going concern note and cited possible regulatory headwinds in Germany and strategic review activities.
IM Cannabis (NASDAQ: IMCC) will report operational and financial results for the third quarter 2025, which ended September 30, 2025.
The company said results will be released on Thursday, November 13, 2025, before the market opens. IM Cannabis operates in Israel and Germany.
IM Cannabis (NASDAQ: IMCC) announced that Chief Financial Officer Uri Birenberg will step down for personal reasons, remaining in the role through January 5, 2026 or an earlier date as determined by the company.
Mr. Birenberg will assist in a structured transition until a successor is appointed. The company noted his two-year tenure and the CEO expressed thanks for his contributions.
IM Cannabis (NASDAQ: IMCC) announced on Oct 23, 2025 a non-binding term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million.
Consideration may include cash, IMC shares and performance-linked earn-outs. The deal is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions, and may not be completed as proposed. The move follows IMC's exploration of additional business activities to enhance long-term growth and shareholder value.
IM Cannabis (NASDAQ:IMCC), a medical cannabis company operating in Israel and Germany, announced significant changes to its Board of Directors effective September 15, 2025. The company appointed Asaf Yitzhaik and Eli Zamir to replace departing board members Shmulik Arbel and Brian Schinderle.
Oz Adler has been appointed as the new Chairman of the Board, replacing Oren Shuster, who continues as CEO and director. The new board members bring extensive experience in retail, real estate, finance, and capital markets. Additionally, the company announced plans to explore new business opportunities to enhance growth and shareholder value.